Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 299-307

  Doecke, James D ^a,f   Simms, Lisa A ^b   Zhao, Zhen Zhen ^b   Roberts, Rebecca L ^j   Fowler, Elizabeth V ^c   Croft, Anthony ^a   Lin, Angela ^b   Huang, Ning ^b   Whiteman, David C ^b   Florin, Timothy H J ^d,e   Barclay, Murray L ^g,h   Merriman, Tony R ⁱ   Gearry, Richard B ^g,h   Montgomery, Grant W ^b   Radford Smith, Graham L ^a,b,e  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c DEPARTMENT OF AGRICULTURE AND FISHERIES   (Australia)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f Preventative Health Flagship   (Australia)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h CHRISTCHURCH HOSPITAL   (New Zealand)

ⁱ UNIVERSITY OF OTAGO   (New Zealand)

^j UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

ATG16L1; Crohn's disease; IL23R; Interleukin 23 receptor; NOD2; Smoking

Indexed keywords

INTERLEUKIN 23 RECEPTOR; IL23R PROTEIN, HUMAN; INTERLEUKIN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPING TECHNIQUE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ADVERSE EFFECTS; AUSTRALIA; COHORT ANALYSIS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; NEW ZEALAND; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; CASE-CONTROL STUDIES; COHORT STUDIES; CROHN DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; NEW ZEALAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 84921484695     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12674     Document Type: Article

References (54)

1. Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 2002; 347: 417-429.
2. Stjernman H, Tysk C, Almer S, Strom M, Hjortswang H. Factors predicting the outcome of disease activity assessment in Crohn's disease. Inflamm. Bowel. Dis. 2009; 15: 1859-1866.
3. Halfvarson J, Jess T, Magnuson A etal. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm. Bowel. Dis. 2006; 12: 925-933.
4. Radford-Smith GL, Edwards JE, Purdie DM etal. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut. 2002; 51: 808-813.
5. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 1988; 29: 990-996.
6. Ng SC, Woodrow S, Patel N, Subhani J, Harbord M. Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm. Bowel. Dis. 2012; 18: 725-736.
7. Cosnes J, Beaugerie L, Carbonnel F, Gendre J-P. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 2001; 120: 1093-1099.
8. Johnson GJ, Cosnes J, Mansfield J. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment. Pharmacol. Ther. 2005; 21: 921-931.
9. Jostins L, Ripke S, Weersma RK etal. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491: 119-124.
10. Franke A, McGovern DPB, Barrett JC etal. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 2010; 42: 1125-1130.
11. Raelson JV, Little RD, Ruether A etal. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 14747-14752.
12. Taylor KD, Targan SR, Mei L etal. IL23R haplotypes provide a large population attributable risk for Crohn's disease. Inflamm. Bowel. Dis. 2008; 14: 1185-1191.
13. Cummings JR, Ahmad T, Geremia A etal. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm. Bowel. Dis. 2007; 13: 1063-1068.
14. Glas J, Seiderer J, Wetzke M etal. Rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS. ONE. 2007; 2: e819.
15. Weersma RK, Zhernakova A, Nolte IM etal. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am. J. Gastroenterol. 2008; 103: 621-627.
16. Latiano A, Palmieri O, Valvano MR etal. Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World. J. Gastroenterol. 2008; 14: 4643-4651.
17. Lappalainen M, Halme L, Turunen U etal. Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm. Bowel. Dis. 2008; 14: 1118-1124.
18. Weersma RK, Stokkers PCF, Cleynen I etal. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am. J. Gastroenterol. 2009; 104: 630-638.
19. Torkvist L, Halfvarson J, Ong RTH etal. Analysis of 39 Crohn's disease risk loci in Swedish inflammatory bowel disease patients. Inflamm. Bowel. Dis. 2010; 16: 907-909.
20. Leshinsky-Silver E, Karban A, Dalal I etal. Evaluation of the interleukin-23 receptor gene coding variant R381Q in pediatric and adult Crohn disease. J. Pediatr. Gastroenterol. Nutr. 2007; 45: 405-408.
21. Yang SK, Park M, Lim J etal. Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans. Inflamm. Bowel. Dis. 2009; 15: 1385-1390.
22. Duerr RH, Taylor CJ, Brant SR etal. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314: 1461-1463.
23. Hampe J, Franke A, Rosenstiel P etal. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 2007; 39: 207-211.
24. Rioux JD, Xavier RJ, Taylor KD etal. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 2007; 39: 596-604.
25. Tremelling M, Cummings F, Fisher SA etal. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology. 2007; 132: 1657-1664.
26. Prescott NJ, Fisher SA, Franke A etal. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology. 2007; 132: 1665-1671.
27. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1 beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007; 8: 942-949.
28. Wilson NJ, Boniface K, Chan JR etal. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 2007; 8: 950-957.
29. Schmechel S, Konrad A, Diegelmann J etal. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel. Dis. 2008; 14: 204-212.
30. Kamada N, Hisamatsu T, Honda H etal. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm. Bowel. Dis. 2010; 16: 568-575.
31. Di Meglio P, Di Cesare A, Laggner U etal. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS. ONE. 2011; 6: e17160.
32. Ellinghaus D, Ellinghaus E, Nair RP etal. Analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 2012; 90: 636-647.
33. Abraham C, Cho J. InterIeukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel. Dis. 2009; 15: 1090-1100.
34. Sandborn WJ, Gasink C, Gao LL etal. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012; 367: 1519-1528.
35. van der Heide F, Nolte IM, Kleibeuker JH, Wijmenga C, Dijkstra G, Weersma RK. Differences in genetic background between active smokers, passive smokers, and non-smokers with Crohn's disease. Am. J. Gastroenterol. 2010; 105: 1165-1172.
36. Fowler EV, Doecke JD, Simms LA etal. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am. J. Gastroenterol. 2008; 103: 1-8.
37. Gearry RB, Richardson A, Frampton CMA etal. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm. Bowel. Dis. 2006; 12: 936-943.
38. Simms LA, Doecke JD, Roberts RL etal. KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand population. Am. J. Gastroenterol. 2010; 105: 2209-2217.
39. Whiteman DC, Parmar P, Fahey P etal. Association of helicobacter pylori infection with reduced risk for Esophageal Cancer is independent of environmental and genetic modifiers. Gastroenterology. 2010; 139: 73-83.
40. Simkins HMA, Merriman ME, Highton J etal. Association of the PTPN22 locus with rheumatoid arthritis in a New Zealand Caucasian cohort. Arthritis. Rheum. 2005; 52: 2222-2225.
41. Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut. 2008; 57: 903-910.
42. Roberts RL, Gearry RB, Hollis-Moffatt JE etal. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am. J. Gastroenterol. 2007; 102: 2754-2761.
43. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21: 263-265.
44. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur. J. Epidemiol. 2005; 20: 575-579.
45. Amre DK, Mack D, Israel D etal. Association between genetic variants in the IL-23R gene and early-onset Crohn's disease: results from a case-control and family-based study among Canadian children. Am. J. Gastroenterol. 2008; 103: 615-620.
46. Waterman M, Xu W, Stempak JM etal. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm. Bowel. Dis. 2011; 17: 1936-1942.
47. Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease. Gut. 1988; 29: 352-357.
48. Ng SC, Woodrow S, Patel N, Subhani J, Harbord M. Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm. Bowel. Dis. 2012; 18: 725-736.
49. Louis E, Michel V, Hugot JP etal. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003; 52: 552-557.
50. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment. Pharmacol. Ther. 1999; 13: 1403-1411.
51. Di Stefano A, Capelli A, Lusuardi M etal. Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin. Exp. Allergy. 2001; 31: 893-902.
52. Ivanov II, Atarashi K, Manel N etal. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009; 139: 485-498.
53. Benjamin JL, Hedin CR, Koutsoumpas A etal. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm. Bowel. Dis. 2012; 18: 1092-1100.
54. Krishnaprasad K, Andrews JM, Lawrance IC etal. Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: how good are we? A multi-centre Australasian study. J. Crohns. Colitis. 2012; 6: 287-293.